🔴 Biovie is trading 6.16% down

Biovie is trading at $1.37, down -6.16%, with no confirmed company-specific announcement explaining the October 29 decline.

• BioVie’s Long COVID Phase 2 results were reported earlier; the study did not achieve statistical significance across endpoints in the overall intent-to-treat population.
• The Nasdaq was reported down more than 1% amid technology weakness, but available evidence does not establish that as the reason for Biovie’s decline.